RSS Feeds
Metformin Hepatotoxicity
- M. Deutsch, MD;
- D. Kountouras, MD; and
- S. P. Dourakis
- From Hippocration General Hospital, 11523 Athens, Greece.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Approximately 5% of patients with type 2 diabetes mellitus may have mildly elevated serum alanine aminotransferase (ALT) values. In 83% of these patients, ALT levels usually decrease during antidiabetic therapy (1).
Metformin is an oral biguanide with a potent insulin-sensitizing effect …
